Make Better Decisions

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Cipla
Julphar
Covington
Boehringer Ingelheim
Medtronic
UBS
Chubb
Fuji
Harvard Business School

Generated: January 22, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 018029

« Back to Dashboard

NDA 018029 describes RITALIN-SR, which is a drug marketed by Novartis and is included in one NDA. It is available from one supplier. Additional details are available on the RITALIN-SR profile page.

The generic ingredient in RITALIN-SR is methylphenidate hydrochloride. There are thirty-one drug master file entries for this compound. Thirty-five suppliers are listed for this compound. Additional details are available on the methylphenidate hydrochloride profile page.
Summary for 018029
Tradename:RITALIN-SR
Applicant:Novartis
Ingredient:methylphenidate hydrochloride
Patents:0
Therapeutic Class:Central Nervous System Agents
Formulation / Manufacturing:see details
Suppliers and Packaging for NDA: 018029
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
RITALIN-SR methylphenidate hydrochloride TABLET, EXTENDED RELEASE;ORAL 018029 NDA AUTHORIZED GENERIC Sandoz Inc 0781-5754 0781-5754-01 100 TABLET, FILM COATED, EXTENDED RELEASE in 1 BOTTLE (0781-5754-01)

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET, EXTENDED RELEASE;ORALStrength20MG
Approval Date:Mar 30, 1982TE:ABRLD:Yes

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Accenture
Julphar
US Army
Federal Trade Commission
Cantor Fitzgerald
Medtronic
Queensland Health
Colorcon
Deloitte

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot